Breaking News
Sort by:
Top Post
Experimental Cancer Drug May Slow Inflammation Linked to Heart Disease
An experimental drug already tested as a potential treatment for cancer, lung, and Alzheimer’s disease […]
Illumina and GenoScreen Launch Next Generation Sequencing Innovation to Eliminate Tuberculosis in Africa
Illumina, a global leader in DNA sequencing and array-based technologies, and GenoScreen, an innovative genomics […]
Celyad Oncology Appoints Georges Rawadi as Its New CEO
Celyad Oncology, a biotechnology company focused on innovative technologies for chimeric antigen receptor (CAR) T-cell […]
Companion Spine Closes $60.1 Million Series A Funding Round
Companion Spine, the French-American specialist in interventional spine pain-management surgery, today announced the successful closing […]
EVERSANA® Announces Partnership with ChemoMouthpiece, LLC to Support U.S. Launch & Commercialization of Medical Device to Help Cancer Patients Manage and Treat Oral Mucositis
EVERSANA, a leading provider of commercialization services to the life science industry, today announced a […]
Vividion Therapeutics Promotes Matt Patricelli to Chief Scientific Officer
Vividion Therapeutics, a biopharmaceutical company utilizing novel discovery technologies to unlock high-value, traditionally undruggable targets […]
GT Medical Technologies Raises $45 Million in Oversubscribed Series C Financing Led by Gilde Healthcare
GT Medical Technologies, a medical device company dedicated to improving the lives of patients with […]
Genprex CEO Commends FDA's Initiative to Accelerate Approval Process for Gene Therapies
Rodney Varner, CEO of Genprex, a clinical-stage gene therapy company focused on developing life-changing therapies […]
OliX Pharmaceuticals Receives Regulatory Approval to Commence Phase 1 Clinical Trial of Treatment of Androgenic Alopecia
OliX Pharmaceuticals, a leading developer of RNAi therapeutics, announced today that it has received approval […]
Bayer Expands Global Clinical Program for NUBEQA® (darolutamide) in Prostate Cancer
Bayer further expands the global clinical development program for NUBEQA (darolutamide) in prostate cancer. The […]
BIOTECanada Welcomes Government of Canada’s Strategy on Improving Access to Care for Patients with Rare Diseases
BIOTECanada welcomes the government’s dedicated investment of $1.5 B over 3 years to advance effective […]
- Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
- Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
- DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
- Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
- Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more